Your browser doesn't support javascript.
loading
Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain, Lokesh; Chain, Anne S Y; Tatosian, Daniel A; Hing, Jeremy; Passarell, Julie A; Kauh, Eunkyung A; Lai, Eseng.
Affiliation
  • Jain L; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Chain ASY; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Tatosian DA; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Hing J; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA.
  • Passarell JA; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA.
  • Kauh EA; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Lai E; Merck & Co., Inc., Kenilworth, NJ, USA.
Br J Clin Pharmacol ; 85(12): 2759-2771, 2019 12.
Article in En | MEDLINE | ID: mdl-31454094
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrans / Diabetes Mellitus, Type 2 / Renal Insufficiency / Dipeptidyl-Peptidase IV Inhibitors / Heterocyclic Compounds, 2-Ring / Hypoglycemic Agents / Kidney Failure, Chronic / Models, Biological Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2019 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrans / Diabetes Mellitus, Type 2 / Renal Insufficiency / Dipeptidyl-Peptidase IV Inhibitors / Heterocyclic Compounds, 2-Ring / Hypoglycemic Agents / Kidney Failure, Chronic / Models, Biological Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Br J Clin Pharmacol Year: 2019 Type: Article Affiliation country: United States